{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-026232","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-06-24T19:48:37+00:00","discovered_at":"2026-06-24T19:49:00.219169+00:00","generated_at":"2026-06-24T19:49:25.524102+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Ionis' TRYNGOLZA for severe hypertriglyceridemia, cuts pancreatitis risk 91%","bullets":["FDA approved TRYNGOLZA (olezarsen) as adjunct to diet to reduce triglycerides and risk of acute pancreatitis in adults with sHTG (TG ≥500 mg/dL).","Phase 3 CORE/CORE2: fasting TG lowered up to 72% vs placebo at 6 months; acute pancreatitis events reduced up to 91%.","86% of patients achieved TG <500 mg/dL at 12 months; NNT to prevent one acute pancreatitis: 20 overall, 4 in highest-risk subgroup.","Available in 50 mg or 80 mg dose, self-administered monthly via autoinjector; U.S. launch expected in July 2026.","This is Ionis' first independent commercial launch in a prevalent disease, marking a major milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-026232","json":"https://secwatch.observer/filing/0001140361-26-026232.json","markdown":"https://secwatch.observer/filing/0001140361-26-026232.md","text":"https://secwatch.observer/filing/0001140361-26-026232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/0001140361-26-026232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:49:25.524102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}